Chapter 8: Cancers of the Female Reproductive Tract

Ovarian cancer frequently presents at advanced stages because early manifestations are nonspecific gastrointestinal symptoms, with most cases arising from epithelial cells lining the ovary or fallopian tube; genetic susceptibility through BRCA1 and BRCA2 mutations significantly elevates lifetime risk, and treatment emphasizes maximal tumor debulking followed by platinum-based chemotherapy regimens. Endometrial carcinoma represents the most common gynecologic malignancy and develops primarily in response to prolonged estrogen stimulation without adequate progesterone-mediated protection, typically manifesting as abnormal uterine bleeding in postmenopausal women; diagnosis relies on transvaginal ultrasonography followed by tissue confirmation through endometrial sampling. Cervical cancer pathogenesis is intrinsically linked to persistent infection with oncogenic human papillomavirus types, which initiate malignant transformation within the transformation zone at the squamocolumnar junction; this cancer remains largely preventable through vaccination programs targeting HPV before sexual exposure and detectable through systematic screening with cytological evaluation and subsequent colposcopic examination of abnormal findings. Vaginal and vulvar malignancies occur less frequently but predominantly manifest as squamous cell histology, often developing from chronic inflammatory conditions, previous HPV infection, or precancerous intraepithelial lesions of the vulva that progress to invasive disease. Comprehensive management integrates surgical approaches including tumor resection and lymph node assessment, radiation therapy for local control and adjuvant treatment, and systemic chemotherapy based on stage and histologic grade, while prevention strategies encompassing vaccination, routine screening protocols, and patient education remain essential components of gynecologic oncology practice.